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Thyroid hormones are key players in regulating brain development. Thus, transfer of
appropriate quantities of thyroid hormones from the blood into the brain at specific
stages of development is critical. The choroid plexus forms the blood-cerebrospinal fluid
barrier. In reptiles, birds and mammals, the main protein synthesized and secreted by the
choroid plexus is a thyroid hormone distributor protein: transthyretin. This transthyretin
is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood
into the cerebrospinal fluid. Maximal transthyretin synthesis in the choroid plexus occurs
just prior to the period of rapid brain growth, suggesting that choroid plexus-derived
transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to
when thyroid hormones are required for rapid brain growth. The structure of transthyretin
has been highly conserved, implying strong selection pressure and an important function.
In mammals, transthyretin binds T4 (precursor form of thyroid hormone) with higher
affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin
binds T3 with higher affinity than T4. As mammals are the exception, we should not base
our thinking about the role of transthyretin in the choroid plexus solely on mammalian data.
Thyroid hormone transmembrane transporters are involved in moving thyroid hormones
into and out of cells and have been identified in many tissues, including the choroid
plexus. Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane
transporters and leave the choroid plexus to enter the cerebrospinal fluid via either thyroid
hormone transmembrane transporters or via choroid plexus-derived transthyretin secreted
into the cerebrospinal fluid. The quantitative contribution of each route during development
remains to be elucidated. This is part of a review series on ontogeny and phylogeny of brain
barrier mechanisms.
Keywords: blood-cerebrospinal fluid barrier, brain, choroid plexus, development, evolution, thyroid hormones,
transthyretin, thyroid hormone transporters
THYROID HORMONES
Thyroid hormones (THs) are key players in regulating develop-
ment of the brain. Insufficient THs during prenatal development
in humans can lead to cretinism and mental retardation, whereas
insufficient THs in adult life can result in fatigue, lethargy, men-
tal impairment, weight gain, cold intolerance and in severe cases,
clinical depression. THs act mainly by regulating transcription of
specific genes. THs are synthesized in the thyroid gland and are
secreted into the blood. Most of the TH secreted from the thyroid
gland is the precursor form (T4). About 80% of the active form
(T3) is generated by deiodination of T4 to T3 in target tissues.
In the blood, >99% of TH is bound to specific plasma proteins
known as TH distributor proteins. Because THs are lipophilic
they partition between the lipid phase and the aqueous phase
with a ratio of 20,000:1 (Dickson et al., 1987). The binding of
THs to TH distributor proteins prevents avid partitioning of THs
into the lipid membranes of cells and ensures that there is a suf-
ficiently large pool of TH circulating in the blood (Mendel et al.,
1987). In humans, the main TH distributor proteins are albumin,
transthyretin (TTR) and thyroxine-binding globulin (TBG), all
of which are synthesized by the liver. In addition, a small frac-
tion is distributed by lipoproteins including ApoB100 (Benvenga
et al., 1989). The free hormone hypothesis states that it is the
free hormone in blood (not the protein-bound hormone) that is
important for biological activity (Mendel, 1989). Thus, THs must
dissociate from the distributor proteins before they can exert their
effects.
In human blood 99.97% of T4 and 99.70% of T3 is bound to
the TH distributor proteins (Mendel, 1989). Of these, TBG has
the highest affinity for T4 and T3 (1.0 × 1010 M−1 and 4.6 ×
108 M−1, respectively), TTR has intermediate affinity (7.0 × 107
M−1 and 1.4 × 107 M−1, respectively) and albumin has the
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lowest affinity (7.0 × 105 M−1 and 1.0 × 105 M−1, respectively).
Together, these three TH distributor proteins form a buffering
network for free T4 in blood, which could help to protect against
hypothyroidism (abnormally low levels of free TH in blood) or
hyperthyroidism (abnormally high levels of free TH in blood)
(Schreiber and Richardson, 1997). The older literature and some
modern text books state that the role of TH distributor proteins
in blood is to overcome low TH solubility. However, the con-
centration of free T4 in human blood is about 25 pM and the
maximum solubility of T4 in physiological saline is 2.3μM, i.e.,
about 100,000 times the concentration of free T4 (Schreiber and
Richardson, 1997). Therefore, TH distributor proteins must play
a role other than to aid the solubility of THs in the blood and CSF.
The concentrations of each of the TH distributor proteins
in adult human blood varies greatly: TBG at 0.015 g/l, TTR at
0.25 g/l and albumin at 42 g/l. Traditionally it has been believed
that in blood, TBG distributes about 75% of thyroid hormones,
TTR distributes 15% and albumin transports about 10%. Because
TBG binds about 75%, it is sometimes referred to as the “most
important” thyroid hormone distributor. However, this is too
simplistic, as the biological importance is related to the deliv-
ery of THs to cells, which is dependent on the dissociation rates
of T3 and T4 from the distributor proteins and capillary transit
times. To determine which of the three TH distributor proteins
contributes most effectively to hormone delivery to tissues, the
dissociation rates and the capillary transit times have to be consid-
ered. In brief, the dissociation rates for T4 and T3 from TBG are
0.018 and 0.16 s−1, respectively; from TTR are 0.094 and 0.69 s−1,
respectively and from albumin are 1.3 and 2.2 s−1, respectively
(Mendel and Weisiger, 1990). Thus, given the capillary transit
times for various tissues (Mendel et al., 1989), TTR is responsible
for much of the immediate delivery of THs to tissues (Robbins,
2000).
THs have multiple mechanisms of action which can be
grouped into “genomic” and “non-genomic” mechanisms of
action. Non-genomic mechanisms include membrane-initiated
mechanisms via binding to specific integrins (Davis et al., 2005,
2011; Lin et al., 2012); cytosolic kinase-initiated interactions
which have non-genomic effects on glucose metabolism (Moeller
et al., 2006, 2011) and rapid activation of kinases in signaling cas-
cades in mitochondria resulting in altered fatty acid metabolism
(Sayre and Lechleiter, 2012). The genomic pathway, which is
generally better known and studied, involves thyroid hormone
receptors (TRs). Free (unbound) THs enter target cells via the TH
transmembrane transporters (Hennemann et al., 2001), which
are responsible for influx and efflux of THs from cells. For
genomic actions of THs within the cell nucleus, T4 can be deiod-
inated to T3 (considered the “active” form of TH). The family of
deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g.,
T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015).
T3 exerts genomic effects by binding to TRs which are nuclear
transcription factors. T3 can bind TRs either in the cytoplasm
and translocate into the nucleus, or bind TRs in the nucleus.
T3 binding to TR hetero-dimer complexes on thyroid response
elements in the promotor of specific genes causes dissociation
of co-repressor proteins and association of co-activator proteins.
The resulting complex then initiates transcription of genes that
are positively regulated by THs. Some genes are negatively regu-
lated by THs, whereby binding of T3 induces the opposite changes
and turns off transcription. Thus, it is crucial that the appropriate
concentration of THs is present in the critical regions of the brain
at each stage of development, to ensure normal brain maturation.
This requires that sufficient (but not excess) THs move from the
blood into the brain at critical stages of development. There are
several pathways for THs to move from the blood into the CSF,
but this review will focus on the route via the choroid plexus i.e.,
the blood-CSF barrier.
THE CHOROID PLEXUS
The choroid plexus is a villous structure located in the lateral,
third and fourth ventricles of the brain and is the site of the blood-
CSF barrier. The structure of the choroid plexus is similar in all
vertebrates studied to date (Ek et al., 2005). The blood supply
to the choroid plexus comes from two posterior choroidal arter-
ies, which branch from the internal carotid arteries. The rate of
blood flow to the choroid plexus has been estimated to be about
3.5 faster than that to the rest of the brain (Zheng, 2005). The
choroid plexus epithelial cells are joined by tight junctions, giv-
ing the tissue its barrier properties (Ek et al., 2005). The choroid
plexus produces about 70%of the CSF, and thus has amajor influ-
ence on its composition (Cserr, 1971). In humans the total CSF is
replaced about four times per day (Brown et al., 2005). In compar-
ison to the blood, whichmixes, the CSF has a pipeline type of flow
which does not mix. Consequently, the composition of the CSF
can vary depending on the site from which it is sampled (Cserr,
1971). The choroid plexus barrier ensures that the composition
of the CSF is very different to that of the blood. For example, in
adult mammals, the CSF has only about 0.5% total protein con-
centration compared to that in the blood (Brown et al., 2005) and
the relative ratios of proteins in the blood compared to the CSF
differ markedly. However, the total protein concentration in the
CSF changes during development, peaking early in development
and then gradually decreasing to adult levels (Saunders, 1992).
For a comprehensive summary of the development of the choroid
plexus (see Ek et al., 2005).
TTR SYNTHESIS BY THE CHOROID PLEXUS
The first description of TTR synthesis in the brain was in 1985
(Soprano et al., 1985). Soon after, Schreiber’s group identified
TTR mRNA as being located only in the choroid plexus of the
brain (Dickson et al., 1985) and then specifically in the choroid
plexus epithelial cells (Stauder et al., 1986). The first experi-
ments suggesting that TTR synthesis by the choroid plexus was
involved in the movement of TH from the blood into the CSF
were published in 1987. 125I-T4 was injected into the blood of
rats and was detected in various brain structures: initially it accu-
mulated in the choroid plexus to ∼250% the level in blood.
Thereafter, 125I-T4 accumulated in the CSF, after which it began
to appear in the cortex and striatum of the brain. However, when
the analogous experiment was repeated using 125I-T3, there was
no specific accumulation of 125I-T3 in the choroid plexus. This
was interpreted as TTR synthesis by the choroid plexus being
involved in the movement of T4 but not T3, from the blood
across the choroid plexus into the CSF (Dickson et al., 1987). TTR
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synthesized by the choroid plexus was shown to be secreted into
the CSF and not into the blood (Schreiber et al., 1990; Duan et al.,
1991) i.e., unidirectional secretion of TTR by the choroid plexus
100% into the CSF. Then Köhrle’s group demonstrated that the
TTR-T4 complex from the blood is not transported as such into
the CSF; and the movement of T4 from the blood into the CSF is
dependent on the concentration of free T4 in the serum and on
T4 binding to choroid plexus-derived TTR i.e., if the TH bind-
ing capacity of TTR was disrupted, then TH did not cross the
choroid plexus (Chanoine et al., 1992). Schreiber’s group showed
that if protein synthesis was blocked in a choroid plexus epithe-
lial monolayer cell culture system, then T4 did not accumulate
in the apical chamber (Southwell et al., 1993). Furthermore, the
concentration of free T4 is higher in CSF than in the blood, thus,
the unidirectional secretion of TTR (or TTR-T4) was moving T4
against the free T4 gradient (Southwell et al., 1993). These were
the key experiments suggesting that the synthesis and secretion of
TTR by the choroid plexus was involved in movement of T4 from
the blood into the CSF.
The choroid plexus is the tissue with the highest concen-
tration of TTR mRNA per gram tissue weight. The adult rat
choroid plexus has an 11 times higher concentration of TTR
mRNA compared to the liver (4.4 vs. 0.39μg TTR mRNA per
gram wet weight) (Schreiber et al., 1990). In chickens, the adult
choroid plexus has a 22 times higher concentration of TTR
mRNA compared to the liver (7.2 vs. 0.33μg TTR mRNA per
gram wet) (Duan et al., 1991). Furthermore, at the protein level,
TTR is the major protein synthesized and secreted by the choroid
plexus of eutherians, marsupials, monotremes, birds, and rep-
tiles (Harms et al., 1991). The common ancestor of those animals
whose choroid plexus specializes in TTR synthesis and secre-
tion are the stem-reptiles, whose brains showed the first traces
of neocortex (Kent, 1987). As THs are lipophilic, the increase in
lipid volume of the brain could have been a selection pressure
in turning on TTR synthesis in the choroid plexus and secret-
ing it into the CSF, to act as a TH-binding protein in the CSF,
thereby reducing the partitioning of THs into the lipid mem-
branes and allowing a greater distribution of TH throughout the
CSF (Schreiber and Richardson, 1997). Thus, the onset of TTR
synthesis in the choroid plexus is suggested to have occurred
at the stage of the stem-reptiles, about 300 million years ago
(Schreiber and Richardson, 1997). TTR is synthesized in the liver
of amphibians and fish during specific stages of development (see
Richardson, 2007), but until now synthesis of TTR in the choroid
plexus of amphibians and fish has not been described [although
TTR mRNA has been detected in whole brain of sea bream
(Santos and Power, 1999)]. The main protein synthesized and
secreted by amphibian choroid plexus is a lipocalin (Achen et al.,
1992), which could be the functional precursor of choroid plexus-
derived TTR, as lipocalins are known to bind small hydrophobic
molecules. That the choroid plexus specializes in the synthesis and
secretion of TTR in such a great range of vertebrates is also sug-
gestive of an important function. Furthermore, the amino acid
sequence of TTRs across all vertebrates is so highly conserved,
that it forms a single motif (Hennebry et al., 2006). Such high
conservation of primary structure can be explained by extremely
strong selection pressures during the past 500 million years.
ALTRICIAL vs. PRECOCIAL BRAIN DEVELOPMENT AND TTR
SYNTHESIS BY THE CHOROID PLEXUS
The brain develops at different rates in different vertebrate
species. At the time of birth, the brain of precocial animals (e.g.,
chickens, sheep) is significantly further developed than the brains
of altricial animals (e.g., rats, mice). Therefore, it is of interest to
compare the ontogeny of TTR synthesis in the choroid plexus of
altricial animals compared with precocial animals.
In rats (23 days gestation), TTR mRNA was first detected in
the choroid plexus at E12.5 in the 4th ventricle, at E13.5 in the
lateral ventricles, and at E17.5 in the third ventricle. The propor-
tion of TTR mRNA in total RNA increased 40-fold from E12.5
until birth (Fung et al., 1988). Because the choroid plexus devel-
ops faster than many other parts of the brain (Sturrock, 1979),
part of this 40-fold increase in TTR mRNA could have been due
to the increase in size of the choroid plexus with respect to the
size of the brain. The peak of TTR mRNA as a proportion of total
brain mRNA (about 140% the level in adults) occurred 2 days
before birth, just prior to the period of fastest brain growth. By 8
days after birth, TTR mRNA levels had decreased to adult levels
(Fung et al., 1988).
In sheep (155 days gestation), TTR mRNA was detected in
choroid plexus from very early embryos (Tu et al., 1990). In
sheep, the maximum increase in size of the choroid plexus (E70)
occurred before that of the rest of the brain (E105). At E40 the
proportion of TTR mRNA in total mRNA was 34% of that in
adult choroid plexus. By E90, this had increased to 70% of the
adult value, and stayed constant at this level during the remainder
of gestation (Tu et al., 1990).
In sheep (precocial), the maximal increase in brain weight
occurred 50 days before birth (Tu et al., 1990), whereas in rats
(altricial), the maximal increase in brain weight was about 9 days
after birth (Fung et al., 1988). The ratio of choroid plexus weight
to total brain weight in sheep decreased to a stable value about 20
days before birth (Tu et al., 1990), whereas that for rats occurred
about 15 days after birth (Fung et al., 1988). For both species, the
choroid plexus had its maximal growth rate prior to that of the
rest of the brain.
The critical period of brain development which is dependent
on THs is earlier for precocial animals than for altricial ani-
mals (Fisher and Polk, 1989). The maximum TTR mRNA level
in the choroid plexus of sheep (precocial) occurred during the
first half of gestation, whereas in rats (altricial), it occurred only
2 days prior to birth. If TTR is involved in moving THs across
the choroid plexus into the brain, and if this TTR then has a role
in TH distribution within the CSF, the timing of the maximal
synthesis of TTR by the choroid plexus is highly appropriate.
In summary, in the 1990s it was proposed that T4 bound to
a TH distributor protein in blood, is in equilibrium with free T4
which is lipophilic, so partitions into the choroid plexus. Within
the choroid plexus, the newly synthesized TTR by the epithe-
lial cells binds to the T4 that entered the choroid plexus from
the blood. Choroid plexus-derived TTR is 100% secreted into
the CSF (not into the blood), so the TTR-T4 complex would be
secreted into the CSF, followed by its distribution via the CSF to
the brain tissue. Thus, the TTR synthesized by the choroid plexus
is involved in moving T4 from the blood into the CSF, against
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the free T4 gradient (Chanoine et al., 1992; Southwell et al., 1993;
Schreiber and Richardson, 1997). We now know some of these
concepts to be outdated (see below).
HUMANS LACKING TTR HAVE NOT BEEN REPORTED
Cases of humans lacking either of the other two TH distrib-
utor proteins: albumin (Minchiotti et al., 2013) or thyroxine-
binding globulin (Refetoff, 1989) have been described. Such peo-
ple are apparently healthy and without overt clinical symptoms.
However, no humans lacking TTR have been reported. In the
1990s the hypothesis was that because TTR is the only TH distrib-
utor protein synthesized in the brain, is secreted unidirectionally
across the apical surface of the choroid plexus epithelial cells into
the CSF, its role in the movement of TH from the blood into the
CSF, its intermediate affinity for T4 (between those of albumin
and thyroxine-binding globulin), and its role is being the most
effective at distributing T4 to cells (see above), that it was thought
to be crucial for survival, most probably due to the requirement of
adequate amounts of TH for normal CNS development (Harms
et al., 1991).
There are cases of humans with mutations in TTR resulting in
higher affinity for THs, including Gly6Ser (∼12% of the popula-
tion), Thr119Met, Ala109Thr, and Ala109Val (Refetoff et al., 1996
and references therein). Of these four variants, only Ala109Thr
resulted in affected individuals consistently having elevated serum
T4 levels (Moses et al., 1982) [although Ala109Val individuals had
elevated rT3 levels (Refetoff et al., 1996)]. More than 100 point
mutations in human TTR result in TTR amyloidosis (familial
amyloidotic polyneuropathy) (Benson, 2009). Whilst the variant
TTRs can have differing affinities for T4 (Rosen et al., 1993) the
patients are generally euthyroid (no publications indicating oth-
erwise; and personal communication from Merrill Benson). This
is possibly because in the blood, only about 1 in 200 TTRs have a
TH bound. Therefore, if some of this TTR is deposited as amyloid
then it might not affect overall TH distribution. The point being
made here is that whilst there are diseases associated with TTR,
there are no humans without TTR, whereas there are healthy
humans without either albumin or thyroxine-binding globulin.
However, the function of TTR synthesized by the choroid
plexus has been debated. Some believe it to be involved with the
movement of T4 from the blood into the CSF (based on the func-
tional, developmental and evolutionary data presented above),
whilst others dispute this (read below). The controversy arose
when TTR null mice were created and were essentially without
an overt phenotype.
TTR NULL MICE
The production of TTR null mice (Episkopou et al., 1993) that
were viable and fertile threw the above hypothesis on the role
of choroid plexus-derived TTR into debate. TTR null mice had
reduced levels of total T4, total T3, retinol, and retinol-binding
protein in their blood, but did not show any overt phenotype.
Consequently, some concluded that TTR was not important for
THs to reach the brain e.g., (Palha et al., 1994, 1997, 2000). One
study concluded that there were no differences in the distribution
of the THs to tissues of TTR null mice compared with wild-
type mice, except in the choroid plexus, where the T4 level was
14% in the TTR null mice compared to wild-type mice (Palha
et al., 2000). A semi-quantitative morphological study suggested
that wildtype and TTR null mice that had been injected intra-
venously with 125I-T4 or 125I-T3 did not show any difference in
TH distribution throughout their brains (Palha et al., 2002). This
bolstered the interpretation that TTR is not an important TH
distributor and that TTR null mice should be considered euthy-
roid (Palha et al., 1994, 2000; Palha, 2002). However, this did not
appear to correspond to the earlier data showing that choroid
plexus-derived TTR was involved with movement of T4 from the
blood into the brain (Dickson et al., 1987; Schreiber et al., 1990;
Chanoine et al., 1992; Southwell et al., 1993).
Soon thereafter, the regulation of neural stem cell cycle in
the subventricular zone of adult rodent brain was shown to be
dependent on TRα/TH by influencing both cell proliferation and
apoptosis (Lemkine et al., 2005). Consequently, it was hypothe-
sized that if TTR was involved in the delivery of THs to the neural
stem cell niche, then this population of cells in TTR null mice
would be affected. Indeed, TTR null mice were shown to have
reduced apoptosis of neural stem cells in the subventricular zone
compared to wildtype mice. Furthermore, the level of apoptosis
was similar to that of hypothyroid wildtype mice, implying a sig-
nificant reduction of TH delivery to neural stem cells in this niche
(Richardson et al., 2007). It was suggested that because the dis-
sociation rate of T4 from albumin differs so significantly to that
of T4 from TTR, and because the concentration of albumin in
the CSF is significantly lower than that in the blood, that in the
absence of TTR, albumin would be unlikely to distribute signif-
icant amounts of TH beyond the ependymal layer of the brain,
resulting in the reduction of TH reaching the subventricular zone
dur to a shallower TH gradient (Richardson et al., 2007). This
study highlighted the importance of TTR in delivering THs to
at least one of the two populations of neural stem cells in adult
mammalian brain.
Until then, all studies involving TTR null mice had been
focussed on adult mice. However, it is well known that THs affect
growth and development, particularly of the CNS (Morreale de
Escobar et al., 1987). In severe cases, TH deficiency in human
babies during gestation results in stunted growth and mental
retardation. Therefore, several aspects of growth known to be
influenced by TH were examined during post-natal development
in TTR null mice. The absence of TTR resulted in delays in
several TH-regulated events including bone growth, CNS matu-
ration, intestine and muscle development and in weaning (Monk
et al., 2013). Furthermore, there was no specific accumulation of
125I-T4 in the choroid plexus of adult TTR null mice, following
intravenous injection. This was in stark contrast to the accumu-
lation of 125I-T4 in the choroid plexus of adult wildtype mice,
following intravenous injection (Monk, 2006). This delay in TH-
regulated events in the CNS of TTR null mice indicated that TTR
has a role in TH delivery in the CNS during development.
In summary, there was strong evolutionary and developmen-
tal evidence that choroid plexus-derived TTR was important for
moving THs into the brain, but this was not backed-up by analy-
ses of TTR null mice. Therefore, there had to be another mech-
anism for THs to enter the brain and presumably the choroid
plexus.
Frontiers in Neuroscience | Neurogenomics March 2015 | Volume 9 | Article 66 | 4
Richardson et al. Thyroid hormones through choroid plexus
TH TRANSMEMBRANE TRANSPORTERS
The first publication on TH transport that indicated an energy-
dependent process for TH uptake into cells was in 1954
(Christensen et al., 1954) but was “lost” in the literature for
decades. In the 1970s Rao demonstrated that TH entry into cells
was temperature-dependent, saturable, high-affinity, and low-
capacity, ligand specific, could transport against a gradient and
required metabolic energy (Rao, 1981). Yet some researchers
missed these publications and believed that because THs could
avidly partition into cell membranes, they could diffuse across the
membrane as a mode of entry into cells. For a history of hypothe-
ses about TH entry into cells, see (Hennemann et al., 2001).
Currently, it is known that THs enter cells via TH transmembrane
transporters, which participate in the influx and efflux of THs
into and out of cells. Several classes of TH transmembrane trans-
porter proteins that belong to the family of solute carrier (Slc)
transporters have been identified e.g. organic anion transporting
polypeptides (OATPs), monocarboxylate transporters (MCTs)
and L-type amino acid transporters (LATs), and actively partic-
ipate in entry and exit of THs into and out of cells (Visser et al.,
2011).
Several TH transmembrane transporters have been localized
to the choroid plexus (Mayerl et al., 2012) and their distribution
in the choroid plexus differs between species (Wirth et al., 2014).
Most TH transmembrane transporters identified to date are
promiscuous with respect to the range of metabolites they trans-
port. OnlyMCT8 has been identified as being specific to transport
of THs and their derivatives (Kinne et al., 2010). Intriguingly,
there exists dramatic species-specificity in TH transmembrane
transporters deficiency phenotypes. For example, human males
with MCT8mutations present with mental retardation (IQ<40),
speech deficits and severe neurological abnormalities (known as
the Allan-Herndon-Dudley syndrome), whereas MCT8 null mice
are without an overt neurological phenotype (Kersseboom and
Visser, 2011). The discovery of the suite of TH transmembrane
transporters, particularly in the choroid plexus, was important in
understanding how TTR null mice were without an overt pheno-
type. The difference in phenotype between MCT8 variant human
males and MCT8 null mice, could point toward elucidating why
TTR null mice are viable, yet no human lacking TTR has been
reported. Possibly, this could be due to different combinations of
TH transmembrane transporters in the choroid plexus and at the
blood-brain barrier, thereby partially compensating for the lack
of choroid plexus-derived TTR in mice (but equivalent mecha-
nisms lacking in humans). For example, Lat2 is synthesized in the
choroid plexus of mice but not in the choroid plexus of humans
(Wirth et al., 2009) or chickens (Darras et al., 2015). This may
be an explanation for the mild phenotype of TTR null mice, yet
the apparent absence of humans lacking TTR. For a more detailed
discussion on the role of TH transmembrane transporters, deiod-
inases and the establishment of TH gradients across membranes,
see a comprehensive review by Schweizer and Kohrle (2013).
The majority of current information on TH transmembrane
transporters has been derived from only human and rodent data.
A recent, comprehensive review on expression of TH transmem-
brane transporters during development in zebrafish, Xenopus
tropicalis, chicken, and mouse (Darras et al., 2015) highlights
howmuch is still unknown. Whilst the developing choroid plexus
has only been analyzed for TH transmembrane transporters in
a few species, interesting differences are emerging. For example,
zebrafish choroid plexus does not synthesize MCT8, which con-
trasts with MCT8 synthesis in the choroid plexus of chickens and
rodents. Furthermore, Lat2 is synthesized in the choroid plexus of
mice but not humans (Wirth et al., 2009) and appears to be totally
absent in chickens (Darras et al., 2015).
From an evolutionary perspective, we need to elucidate the
developmental expression profiles for each of the TH trans-
membrane transporters in the choroid plexus from a variety of
vertebrates representing each of the vertebrate classes. In partic-
ular, a comparison of expression of TH transmembrane trans-
porters in the choroid plexus of animals who synthesize TTR in
their choroid plexus (reptiles, birds, and mammals) with those
who do not synthesize TTR in their choroid plexus (fish and
amphibians) should be made. Furthermore, comparisons of TH
transmembrane transporter expression profiles in the choroid
plexus between precocial and altricial species would be intriguing.
A comparison of the expression profiles of TH transmembrane
transporters in mammalian choroid plexus vs. those in choroid
plexus from non- mammals should be made, as mammalian
TTRs are the exception in having higher affinity for T4 than T3.
TTRs from all other vertebrates have higher affinity for T3 than
for T4 (see below). Such studies could shed light on the relative
roles of each of the TH transmembrane transporters and choroid
plexus-derived TTR in the overall movement of THs from the
blood into the CSF during development.
MAMMALIAN TTRs ARE THE EXCEPTION
In all studied species of fish, amphibians, reptiles and birds, TTR
has higher affinity for T3 than T4, whereas in mammals TTR
has higher affinity for T4 than for T3 (Richardson, 2007). Thus,
mammals are the exception in this regard. Is it possible that
whilst TTR made by the choroid plexus of mammals moves T4
into the brain, TTR from other animals moves T3 into the brain?
What could have been the selection pressure for the change to
TTR from distributing T3 to distributing T4? One possibility
could be a greater level of control, requiring an additional level
of regulation (i.e., deiodination of T4 to T3) at the target site.
For example, different regions of the brain generate different
proportions of T3 by local deiodination (van Doorn et al.,
1985). Two features that distinguish mammalian brains from
non-mammalian brains that are regulated (at least in part) by
thyroid hormones are the corpus callosum which is heavily
myelinated, and the highly developed cortex. The point here is
that mammals may be the exception rather than the rule, when
it comes to modes of TH entry into the CNS, so we should
not just consider mammalian data. Furthermore, we have seen
examples between eutherian species, of significant differences in
TH transmembrane transporters (e.g., Lat2).
The literature is often skewed toward data on mam-
mals, especially humans (due to our self-centerd interests in
medicine/disease) and mice (due to the ease of working with
them: inbred strains, short generation times, knock-in/out
genetic manipulations etc), so we should be careful in analysing
data from humans and rodents or eutherian mammals and
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drawing generalized conclusions, which may not be applicable to
all mammals, let alone to all vertebrates. Furthermore, data from
knock-out mice can sometimes raise more questions than they
answer.
CONFUSION ARISING FROMMOUSE KO MODELS OF TH
MOVEMENT INTO THE BRAIN
TTR null mice have 36% T4 levels in their brain compared
to wildtype mice (Palha et al., 1997). This implies that TTR
is responsible for the other 64% of T4 moving into the brain.
However, Mct8/Oatp1c1 double knock-out mice are cited as hav-
ing only 10% TH concentration in their brains compared to wild-
type mice (Muller and Heuer, 2014). However, careful analysis
of the original paper reveals that only the forebrain (and not the
entire brain) was analyzed for TH content (Mayerl et al., 2014).
Furthermore, if TH transmembrane transporters are responsi-
ble for moving significant amounts of TH into and out of the
choroid plexus, then why do TTR null mice have only 14% T4 in
their choroid plexus compared with wildtype mice? How do these
data from TH transmembrane transporter and TTR null mice
correlate with the data from Chanoine et al. (1992)? The quan-
titative contributions of the various mechanisms for TH moving
across the blood-CSF barrier (the choroid plexus) and across the
blood-brain barrier need to be investigated in greater detail.
CURRENT HYPOTHESIS FOR TH MOVEMENT FROM BLOOD
VIA THE CHOROID PLEXUS TO THE CSF
Our current hypothesis for the movement of TH from the blood
via the choroid plexus is depicted in Figure 1. In this Figure, T4
(major form of TH secreted by the thyroid gland) is depicted.
1. T4 dissociates from TH distributor proteins in the blood.
2. T4 enters the choroid plexus via TH transporters.
3. TTR is synthesized by the choroid plexus epithelial cells.
4. Some T4 will bind TTR synthesized in the choroid plexus
epithelial cells.
5. T4 moves out of the choroid plexus into the CSF via either
secretion of the T4-TTR complex; or via TH transmembrane
transporters.
It is worth noting that there is a higher concentration free T4 in
CSF than in blood, so net movement of TH from the blood to the
CSF is against this gradient. Therefore, it would not be surpris-
ing if several mechanisms for moving TH from the blood via the
choroid plexus (and the blood-brain barrier) had evolved.
CONCLUSION
From the above controversy regarding the importance of TTR
synthesis by the choroid plexus, several points support the
FIGURE 1 | Current hypothesis of mechanisms involved with TH
movement from the blood across the choroid plexus into the CSF.
THs are synthesized in the thyroid gland and secreted into the blood,
where >99% are bound by the TH distributor proteins (THDPs) which
include albumin (Alb), transthyretin (TTR), thyroxine-binding globulin
(TBG) and to a lesser extent by specific lipoproteins, depending on
the species and the stage of development. The main form of TH
released from the thyroid gland is T4, so T4 is used as the example
in this schematic. T4 dissociates from TH distributor proteins in the
blood and enters the choroid plexus via TH transmembrane
transporters (which may include Mct8 and Oatp1c1, depending on the
species). TTR is synthesized by the choroid plexus epithelial cells and
is secreted into the CSF. Some T4 binds TTR synthesized in the
choroid plexus epithelial cells. T4 moves out of the choroid plexus
into the CSF via either secretion of the T4-TTR complex or via TH
transmembrane transporters.
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hypothesis that choroid plexus-derived TTR plays a role in the
movement of THs from the blood to the brain and in distributing
THs in the blood and CSF. These points include evolution-
ary, developmental, molecular and functional data. Therefore, it
would follow that TTR synthesized by the choroid plexus would
appear to have an important regulatory role in determining the
delivery of thyroid hormones into the CSF.
In conclusion, there is evidence for twomechanisms for THs to
move out of the choroid plexus into the CSF: (i) secretion of TH
bound to choroid plexus-derived TTR, and (ii) efflux of THs via
TH transmembrane transporters. The relative quantitative con-
tribution of each of these mechanisms during each stage of CNS
development is currently unknown and should be investigated.
Furthermore, perhaps the role played by choroid plexus-derived
TTR is more significant in non-mammalian vertebrates than in
mammals. It would be interesting to analyze the developmental
profiles of TH transmembrane transporters in the choroid plexus
(and in other blood-brain barrier structures) in non-mammalian
vertebrates during development. The delivery of the requisite
concentrations of THs to specific areas of the brain at each stage of
CNS development is so important, that it would be understand-
able for evolution to have positively selected for more than one
strategy for THs to enter the CNS.
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